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 Introduction 
 Vitamins play a distinct role in human physiology, 
metabolism and disease. The physiological role is not part 
of this overview; we concentrate on the role of vitamins 
in the course of inflammatory bowel disease (IBD) and 
for associated complications. Deficiencies of single vita-
mins are rarely endemic, even in developing nations, and 
are more likely to occur either in the context of general 
malnutrition or as a result of diseases with malabsorption 
and/or the need for total parenteral nutrition (TPN). IBD 
is frequently associated with vitamin deficiencies. The 
etiology of decreased vitamin levels in IBD is multifacto-
rial and partly due to a pain-related decrease in food in-
take, e.g. anorexia or else caused by malabsorption i.e. a 
decreased absorption of vitamins by the inflamed mu-
cosa. Intestinal losses caused by the disease [e.g. blood 
and hemoglobin during ulcerative colitis (UC)] may also 
play a role. The most important mechanisms that lead to 
vitamin deficiencies in IBD are summarized in  table 1  [1] . 
 Table 2 summarizes the current literature on the preva-
lence of vitamin deficiencies among IBD patients and rec-
ommended daily allowances  [2–14] . As the supplementa-
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tion of vitamins may significantly improve IBD patients’ 
health status and quality of life, it is important to recog-
nize nutritional deficiencies at an early stage and initiate 
appropriate treatment. Like this, many patients may ex-
perience a further disease aggravation caused by a vita-
min deficiency which could otherwise be easily avoided. 
We consider it unfortunate that somehow the availability 
of highly effective treatment options has decreased the 
attention to the issues we discuss here.
 Water-Soluble Vitamins 
 Thiamine (Vitamin B 1 ) 
 Thiamine is synthesized by a variety of plants and mi-
croorganisms but usually not by animals. Small amounts 
may be synthesized by microorganisms in the gastroin-
testinal tract. Thiamine is absorbed both by an active 
transport process and by passive diffusion. The capacity 
to absorb the vitamin in the human intestine is about
5 mg/day; approximately 25–30 mg is stored in the body. 
The recommended daily allowances for thiamine are giv-
en in  table 2 . The vitamin has a widespread distribution 
in food and is absent only in oils, fats and refined sugar. 
A substantial loss of the vitamin takes place by heating 
food over 100  °  C. 
 The two major manifestations of thiamine deficiency 
involve the cardiovascular system (wet beriberi with ede-
ma, tachycardia and a high-output state) and the nervous 
system (dry beriberi with peripheral neuropathy and the 
Wernicke-Korsakoff syndrome). The patient typically 
has mixed symptoms involving both the cardiovascular 
and nervous systems. Wernicke’s encephalopathy con-
sists of vomiting, nystagmus (horizontal), ophthalmople-
gia, fever, ataxia and progressive mental deterioration 
and eventually a state of overall confusion. Korsakoff ’s 
syndrome consists of retrograde amnesia, an impaired 
ability to learn and (usually) confabulation. Development 
of thiamine deficiency occurs mainly in alcoholics and in 
patients with malabsorption or malnutrition. Several 
case reports have been published describing vitamin B1 
deficiency in patients with Crohn’s disease (CD)  [15–17] . 
Hahn et al.  [15] describe a CD patient on TPN, in whom 
beriberi and Wernicke’s encephalopathy developed be-
cause multivitamin infusions were switched to an oral 
multivitamin formula. Another case report emphasizes 
the dependence of thiamine on magnesium and states 
that if thiamine and magnesium are deficient at the same 
time, both should be substituted simultaneously  [16] .   
 Riboflavin (Vitamin B 2 ) 
 Riboflavin participates in a variety of oxidation-re-
duction reactions. In addition, it is essential to a variety 
of enzymes such as succinate dehydrogenase and mono-
amine oxidase. It is either passively absorbed from the 
gastrointestinal tract as free riboflavin or taken up by an 
active transport. It is excreted in the urine predominant-
ly in the free form, although a small fraction of the daily 
turnover is the result of catabolism by microorganisms in 
the gastrointestinal tract. A deficiency is characterized by 
a sore throat, hyperemia and edema of the oral mucus 
membranes, cheilosis, angular stomatitis, glossitis, seb-
orrheic dermatitis and normochromic, normocytic ane-
mia due to red-cell hypoplasia of the bone marrow. No 
case reports have been published on vitamin B2 deficien-
cy in IBD patients. Two publications report a decreased 
vitamin B 2 intake in CD  [18, 19] and UC  [19] . 
 Niacin (Vitamin B 3 ) 
 Niacin is the generic name for nicotinic acid (pyri-
dine-3-carboxylic acid) and derivatives that exhibit the 
nutritional activity of nicotinic acid. In some sense, nia-
cin is not a ‘true’ vitamin, since it can be synthesized from 
the essential amino acid tryptophan. In humans, an aver-
age of about 1 mg niacin is formed from 60 mg of dietary 
tryptophan. Once niacin has been orally ingested, the vi-
tamin is absorbed rapidly from the intestine by both ac-
tive and passive transport mechanisms. A deficiency in 
niacin is called pellagra, a chronic wasting disease typi-
cally associated with dermatitis, dementia and diarrhea. 
The dermatitis is bilateral and symmetric, and is present 
in sites exposed to sunlight (due to photosensitivity). 
Table 1. P athogenesis of vitamin deficiency in IBD [1]
Reduced food and
vitamin intake
anorexia
fear of eating from abdominal pain
Active inflammation mechanisms unknown
Enteric loss of vitamins exudation from intestinal mucosa
interrupted enterohepatic circulation
Malabsorption loss of absorptive surface from disease,
resection or bypass
stagnant loop syndrome from strictures 
fistulae or surgically created blind loops
Miscellaneous rapid gastrointestinal transit
effects of medical therapy
effects of parenteral nutrition without 
supplements
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Mental changes comprise fatigue, insomnia and apathy, 
which may precede the development of an encephalopa-
thy, characterized by confusion, disorientation, halluci-
nation, loss of memory and eventually organic psychosis. 
Paresthesias and polyneuritis may be the result of coex-
isting deficiencies of other vitamins. Diarrhea, when 
present, results from widespread inflammation of the 
mucous surfaces. Further symptoms such as glossitis, 
stomatitis, proctitis, mental depression, abdominal pain, 
vaginitis, dysphagia and amenorrhea are also described. 
 Pellagra has seldom been described as a complication 
of CD. Only 5 case reports are published in the literature 
 [4–7, 20] . The cause of nicotinic acid deficiency in IBD 
patients may reflect an inadequate intake, malabsorption 
or increased demand. Suggested treatment regimens are 
parenteral administration of niacin at 100 mg/day. 
 Pyridoxine (Vitamin B 6 )  
 Pyridoxine is widely distributed in different kinds of 
foods: muscle meats, liver, vegetables and whole-grain ce-
reals are among the best sources. More than for most vi-
tamins, the demand is increased in pregnancy. The wide-
spread occurrence of this vitamin in food is probably the 
reason that isolated pyridoxine deficiency is rare. How-
ever, some drugs act as pyridoxine antagonists and may 
cause a deficiency; among these are isoniazid and penicil-
lamine. The prevalence of vitamin B 6 deficiency in IBD 
patients was reported to be around 29–30%  [8, 14, 21] . 
Low levels have been associated with hyperhomocystein-
emia among IBD subjects  [22] ; however, the role of a vi-
tamin B 6 deficiency in hyperhomocysteinema etiology 
remains controversial. Several studies support hyperho-
mocysteinemia as a risk factor for both arterial and ve-
nous thromboembolisms especially in IBD patients  [23, 
24] . There is a 4-fold increased risk for theomboembolic 
events in IBD patients, especially in patients with active 
disease. As outlined above, IBD may be associated with 
deficiencies in vitamin B 6 and B 12 that in turn may pro-
mote increased homocysteine levels  [14, 21, 22] . In con-
trast, homocysteine levels were found to be normal in the 
majority of IBD patients, and no elevated homocysteine 
levels were found in those with low vitamin B 6 serum lev-
els  [8] . This questions the role of vitamin B 6 levels regard-
ing the risk of thromboembolism in IBD.
 Cobalamin (Vitamin B 12 ) 
 Like most other B vitamins, cobalamin is water-solu-
ble. The only dietary source is animal products such as 
meat and dairy. During gastric digestion, cobalamin in 
food is cleaved from its binding protein by acid and pep-
sin in the stomach and binds to the R factor which is pro-
duced in the saliva and the stomach. On entering the du-
odenum, the cobalamin-R binder complex is digested, 
releasing the cobalamin, which then binds to intrinsic 
factor (IF, produced by the parietal cells of the stomach). 
The cobalamin-IF complex is resistant to proteolytic 
Table 2. P revalence of vitamin deficiencies in IBD and recommended daily allowances [2]
Vitamin RDA1 Frequency in CD, % Frequency in UC, % Reference 
numberinpatients outpatients inpa tients outpatients
Water-soluble vitamins
Thiamine Vitamin B1 1.5 mg +2 35 n.d. n.d. [3]
Riboflavin Vitamin B2 1.7 mg n.d. n.d. n.d. n.d. –
Niacin Vitamin B3 19 mg n.d. 77 n.d. n.d. [3–7]
Pyridoxine Vitamin B6 2 mg n.d. 4.2–37 n.d. 3.8 [3, 8]
Cobalamin Vitamin B12 2 g 48 3–35 5 2.9–7.5 [3, 8–11]
Folic acid Vitamin B9 200 g 56–62 10–23 30–41 8.6 [3, 8, 10–13]
Ascorbic acid Vitamin C 60 mg + 9.9–84 n.d. 12 [3, 14]
Fat-soluble vitamins
Retinol Vitamin A 1,000 ga 11–50 30 93 18–26 [3, 9, 10, 12, 14]
Cholecalciferol Vitamin D 5 gb 23–75 6–38 35 32 [3, 9, 12]
Tocopherol Vitamin E 10 mgc 0 10–59 40 59 [3, 13]
Menaquinone Vitamin K 80 g + n.d. + n.d. [2]
n. d. = Not determined. 1 Recommended daily allowances expressed as average daily intakes over time in 25- to 50-year old males. 
2 Described, prevalence not reported. a Retinol equivalents. b As cholecalciferol: 10 g cholecalciferol = 400 IU of vitamin D. c -To-
copherol equivalents: 1 mg/day -tocopherol = 1 -TE.
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 digestion and travels to the distal ileum, where specific 
receptors on the mucosal brush borders bind the cobala-
min-IF complex, thereby enabling the vitamin to be ab-
sorbed. Once absorbed, cobalamin is bound to trans-
cobalamin II and is then transported to the liver, bone 
marrow and other cells. Normally, about 2 mg cobalamin 
is stored in the liver, and another 2–3 mg is stored else-
where in the body. In view of the minimum daily require-
ment (1–3   g/d) and a body store of about 5 mg, it would 
require about 3–6 years for a normal individual to be-
come deficient in cobalamin if absorption would cease 
abruptly. Vitamin B 12 deficiency typically results in inef-
fective erythropoiesis and megaloblastic anemia as well 
as sometimes irreversible neurologic and psychiatric ab-
normalities including personality changes, neuropsychi-
atric deficits, parasthesias, ataxia and a shuffling gait. Pa-
tients with CD may be at a particular risk for vitamin B 12 
deficiency due to ileal inflammation or surgical resection 
of the ileum leading to impaired absorption of the vita-
min  [25] . A good review on the prevalence of impaired 
vitamin B 12 absorption and deficiency in CD patients has 
been published by Kulnigg and Gasche  [26] . It has been 
reported that ileal resections  ! 20 cm are not a risk factor 
for developing a vitamin B 12 deficiency. For patients with 
resections of 20–60 cm, a routine monitoring or empiri-
cal therapy with vitamin B 12 is mandatory  [27] . An asso-
ciation with gastric CD had also been recognized  [28] . 
 Vitamin B 12 supplementation is often necessary in pa-
tients with chronic active CD or resection of the terminal 
ileum and during therapy with sulfasalazine, which in-
hibits vitamin B 12 absorption. Unfortunately, supplemen-
tation therapy with vitamin B 12 and folic acid is only per-
formed in 40% of anemic IBD patients in gastroentero-
logical practices in Switzerland compared to 43% in 
tertiary referral centers  [29] . More than 50% of patients 
in need of supplementation do not receive the therapy.
 Folic Acid (Vitamin B 9 ) 
 Folate is synthesized by many different plants and bac-
teria. Fruits and vegetables constitute the primary source 
of the vitamin. Some forms of dietary folic acid are labile 
and may be destroyed by cooking. Folate is absorbed in 
the duodenum and jejunum and a deficiency may be due 
to an inadequate diet, malabsorption or drug interactions 
(e.g. sulfasalazine and methotrexate). Clinical manifesta-
tions occur earlier than with vitamin B 12 deficiency, as 
folate stores last only 1–2 months. Patients with folic acid 
deficiency are more apt to be malnourished than those 
with cobalamin deficiency. The gastrointestinal manifes-
tations of folic acid deficiency consist of diarrhea, cheilo-
sis and glossitis. In contrast to cobalamin deficiency, neu-
rologic symptoms do not occur. The causes of folate defi-
ciencies, especially in IBD patients, are undoubtedly 
usually multifactorial: anorexia, malabsorption, in-
creased disease activity and drug-induced hemolysis 
from sulfasalazine are all important mechanisms in CD. 
It has been proposed that oral folate supplementation 
should be recommended for patients with IBD as an an-
tineoplastic and antithrombotic agent  [30, 31] . Two retro-
spective publications have identified a folate-induced 
protective effect against dysplasia and colorectal cancer 
in patients with UC  [30, 31] . Despite these studies which 
link folate deficiency to an increased risk of cancer in 
IBD, there are currently no prospective studies providing 
evidence for a reduced cancer risk in colitis following 
supplementation. 
 Ascorbic Acid (Vitamin C) 
 In most animals, ascorbic acid can be synthesized from 
glucose. However, humans are unable to synthesize vita-
min C and therefore require it in their diet. Vitamin C has 
a key role as a redox agent for biologic oxidation and is es-
sential in the synthesis of collagen. Many features of vita-
min C deficiency (scurvy) result from these defects in col-
lagen synthesis including capillary fragility that underlies 
the hemorrhagic features, the poor healing of wounds and 
the bone abnormalities of children. Other features of 
scurvy include hyperkeratotic papules in which hairs be-
come fragmented and buried, perifollicular hemorrhages 
and purpura beginning on the backs of the lower extrem-
ities coalescing to become ecchymoses, gum involvement 
that includes swelling, friability, bleeding, loosening of 
teeth and emotional changes. Normochromic, normocyt-
ic anemia is common and is due to bleeding into tissue. 
The first case of scurvy in CD and a confirmatory low 
leukocyte ascorbic acid level was reported in 1979  [32] . 
Gerson and Fabry  [33]  found that in patients with CD, fis-
tula formation might be related to a local ascorbate defi-
ciency; however, these findings were never confirmed in 
larger studies. Aghdassi et al.  [34] conducted a random-
ized, controlled study in which patients with CD in remis-
sion and proven oxidative stress received vitamin C and 
vitamin E supplementation or placebo for 1 month. The 
supplementation significantly decreased all indexes of ox-
idative stress and increased vitamin C and E plasma con-
centrations. These results indicate that patients with CD 
supplemented with antioxidant vitamins E and C reduce 
their oxidative stress. However, whether there would be 
any long-term clinical benefit from antioxidant supple-
mentation has still to be determined.
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 Fat-Soluble Vitamins 
 Vitamin A 
 Vitamin A (retinol) can be either directly ingested or 
synthesized within the body from plant carotenes. The 
best sources of preformed vitamin A are liver, milk and 
kidneys, where it occurs largely in the form of fatty acid 
esters. Retinol is stored as retinyl esters in the liver. The 
normal body pool is 300–900 mg.
 The best-defined function of vitamin A is its role in 
vision. Deficiencies usually result from inadequate 
amounts of the vitamin and provitamins in the diet and 
occur in conjunction with a deficiency of other nutri-
ents. In some developing countries, vitamin A deficien-
cy is a major cause of blindness in the young. In devel-
oped countries, a deficiency is usually due to either in-
testinal malabsorption (as in sprue or after intestinal 
bypass surgery), abnormal storage (liver disease) or the 
enhanced destruction or excretion of the vitamin (pro-
teinuria). Typical symptoms of vitamin A deficiency 
consist of night blindness, dry conjunctiva (xerosis) and 
ulceration and necrosis of the cornea (keratomalacia). 
Some case reports described CD patients with low plas-
ma levels of vitamin A  [35–37] . During acute flares of 
IBD, decreased serum vitamin A levels have been found 
 [38] . Serum concentrations of vitamin A do not depend 
on the localization of disease, previous surgery, dura-
tion of IBD or the age and sex of the patients  [38] . In IBD 
patients in remission, normalization of serum retinol 
levels without substitution of vitamin A has been ob-
served  [38] .
 Newer studies report that vitamin A is an important 
regulator of the human immune system, especially in the 
digestive tract. In fact, vitamin A deficiency induces in-
creased blood interferon gamma and chronic diarrhea 
 [39–41] . Vitamin A also has anti-inflammatory proper-
ties  [42–45] . The cellular effects of vitamin A and its de-
rivatives have been studied in multiple in vitro settings 
and the molecular effects are well described  [46] . Among 
the effects observed is the inhibition of proinflammatory 
interleukin (IL)-17-producing Th17 cells and an induc-
tion of anti-inflammatory T regulatory cells: When co-
lonic biopsies from patients with UC were cultured and 
treated with vitamin A derivatives, the upregulation of 
FOXP3 expression (regulatory, anti-inflammatory T 
cells) and the downregulation of IL-17 expression was ob-
served  [47] . In animal models of colitis treated with vita-
min derivatives, lower levels of proinflammatory cyto-
kines (TNF-alpha, IL-1beta and IL-17) and higher levels 
of regulatory cytokines (IL-10 and TGF-beta) than in un-
treated mice were detected  [47] . Colitis was less severe in 
the animals treated with vitamin A derivative  [42, 47] .
 These finding suggest that vitamin A might be a new 
therapeutic target for the treatment of IBD. On the other 
hand, 2 studies and some case reports have proposed an 
association of IBD and treatment with vitamin A deriva-
tive  [48, 49] . This is in contrast to other epidemiological 
studies that could not find any association of retinoids 
with the onset of IBD.
 Vitamin D 
 Vitamin D is a hormone rather than a vitamin. Hu-
mans get vitamin D from exposure to sunlight, their diet 
and dietary supplements  [50] . With adequate exposure to 
sunlight, no dietary supplements are needed. Solar ultra-
violet B radiation penetrates the skin and converts 7-de-
hydrocholesterol to vitamin D 3 (cholecalciferol). Vitamin 
D from the skin and diet is metabolized in the liver to 
25-hydroxyvitamin D (calcidiol), which is used to deter-
mine a patient’s vitamin D status. 25-Hydroxyvitamin D 
is then metabolized in the kidney to the active form 
1,25-dihydroxyvitamin D (calcitriol). This renal produc-
tion of calcitriol is tightly regulated by levels of plasma 
parathyroid hormone, serum calcium and phosphorous. 
The active hormone is then transported through the 
blood to its target tissue (the small intestine and bone), 
where it regulates calcium homeostasis  [51] . Vitamin D 
deficiency is found in 22–70% of patients with CD and it 
has been proposed that it plays an important role in CD 
pathogenesis  [52] . Several lines of evidence support vita-
min D as a promising environmental factor that may sub-
stantially influence the risk of developing IBD: (1) eco-
logical studies have suggested that the north-south gradi-
ent seen in the incidence of IBD patients (with increased 
incidences of IBD at higher latitudes) might be associated 
with reduced solar ultraviolet B radiation exposure and 
consecutive low vitamin D levels  [53] , (2) studies have 
linked single-nucleotide polymorphisms in the vitamin 
D receptor to increased susceptibilities to CD and UC  [54, 
55] , (3) deficiency of 1,25 dihydroxivitamin D and vita-
min D receptor knock-out in mice increases the severity 
of a dextran sulfate sodium colitis, and administration of 
vitamin D suppresses the expression of several proin-
flammatory genes  [56, 57] and (4) higher predicted plas-
ma levels of 25-hydroxyvitamin D significantly reduce 
the risk for incident CD in women  [58] . 
 Vitamin D appears to have several important actions 
beyond the maintenance of bone health, including vari-
ous effects on the immune system  [59] . It may play a role 
in the treatment of IBD-specific complications such as 
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osteopenia, colorectal neoplasia and depression (for a re-
view see  [51] ). 
 To date, only one randomized placebo-controlled trial 
has been reported assessing the benefits of oral vitamin 
D 3 treatment in CD patients  [60] . In total, 108 CD patients 
in remission were included in this trial; they were ran-
domized to receive either 1,200 IU vitamin D 3 or placebo 
once daily for 12 months. The number of relapses during 
therapy was lower among patients treated with vitamin 
D 3 and calcium (13%) than among patients treated with 
calcium alone (29%), but the difference did not reach sta-
tistical significance. 
 Vitamin E 
 Vitamin E is absorbed from the gastrointestinal tract 
and enters the circulation via the lymph. The vitamin is 
stored in all tissues and these tissue stores can protect 
against vitamin deficiency for long periods. The recom-
mended daily allowance is 10 mg/d (see  table 2 ). The vi-
tamin is widely distributed in food, so a primary defi-
ciency state has never been recognized in otherwise 
healthy children or adults. Vitamin E deficiency may be 
associated with a discrete syndrome especially in intesti-
nal fat malabsorption. The manifestations of deficiency 
include areflexia, gait disturbance, decreased proprio-
ceptive and vibratory sensation and paresis of gaze. To 
date, no case reports on isolated vitamin E deficiency in 
IBD have been published. In a cohort of children with 
IBD, serum levels of vitamin E were within normal values 
and not significantly different to controls without IBD 
 [61] . These results are different from other studies, where 
a low intake of or low-serum concentrations of vitamin E 
in IBD patients were described  [14, 21, 62, 63] . As previ-
ously described, vitamin E supplementation in patients 
with IBD significantly decreases all indexes of oxidative 
stress and increases vitamin E plasma concentrations, in-
dicating the antioxidative properties of this vitamin  [34] .
 Vitamin K 
 Vitamin K (vitamin K 1 ) is present in most edible veg-
etables, particularly in green leaves. Another form of vi-
tamin K (vitamin K 2 ) is produced by intestinal bacteria 
but not in sufficient amounts to supply daily require-
ments. Under ordinary circumstances, about 80% of vi-
tamin K is absorbed from the small bowel into the intes-
tinal lymph. Deficiency can occur in association with 
diseases that interfere with fat absorption. In addition, 
long-term treatment with oral antibiotics may temporar-
ily eliminate intestinal bacteria as a source of vitamin K 
and promote deficiency when the diet is marginal. Vita-
min K deficiency leads to low plasma levels of several co-
agulation factors in the prothrombin complex. Different 
case reports of CD patients with hemorrhagic problems 
have been reported in the literature  [35, 64, 65] . Malab-
sorption is probably the most important cause of vitamin 
K deficiency either from extensive disease or from resec-
tion that is severe enough to interfere with bile salt ab-
sorption. Recently, an interesting observation was pub-
lished: a significant correlation of vitamin K deficiency 
and clinical disease activity was observed in patients with 
CD  [66] . Further prospective studies are required to clar-
ify the role of vitamin K in patients with IBD. 
 Conclusion 
 Vitamins play an important role in the metabolism but 
also in the functions of innate adaptive immunity. The 
important anti-inflammatory roles of vitamins A, D and 
E have been described. Vitamin D substitution may play 
a role in maintenance therapy in IBD. Vitamin deficien-
cies are frequently observed in patients with IBD. Conse-
quently, these patients should be considered, potentially, 
as being malnourished. A regular assessment of their vi-
tamin status should be recommended which could lead 
to specific management, such as suggestions about food 
choices or vitamin supplementation in severe cases. Diet 
counselling is important and has proved to be effective in 
correcting a low nutrient intake in CD patients, and even 
in improving the course of CD  [67, 68] .
 As we have described for vitamins A and D, vitamins 
may be used in the future not only for supplementation 
in the case of deficiencies in IBD patients but also to treat 
active inflammation or to maintain remission.
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